Clinical trial
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute…
NCT00287105 · Rennes University Hospital, Other · Completed
Key facts
| NCT number | NCT00287105 |
|---|---|
| Title | Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children |
| Official title | An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL) |
| Acronym | ESPHALL |
| Lead sponsor | Rennes University Hospital, Other |
| Collaborators | Ministry of Health, France Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia, Philadelphia Chromosome |
| Intervention type | Drug |
| Interventions | Standard chemotherapy + Imatinib |
| Enrollment | 49 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 30, 2016 |
| Completion | Mar 3, 2017 |
| First posted | Feb 6, 2006 |
| Last update posted | May 24, 2023 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: